A novel cancer drug known as EXO-CD24 developed and tested at Tel Aviv Sourasky Medical Center (Ichilov Hospital), demonstrates promising results. Led by Professor Nadir Arber the study was the result of “out-of-the-box thinking” that led to an overwhelmingly positive outcome for this investigational product. The researchers here shared last week that 29 out of 30 patients with moderate-to-severe COVID-19 that participated in this study involving the study drug EXO-CD24 recovered within three to five days. This early-stage Phase 1 safety trial investigating EXO-CD24 has created a buzz in Israel research circles, and beyond as the Prime Minister paid the investigators a visit.
Led by Dr. Nadir Arber of the Integrated Cancer Prevention Center at Tel Aviv Sourasky Medical Center (Ichilov Hospital), this drug was first studied in ovarian cancer. The therapy, inhaled once daily for five days, was originally developed to treat cancer by regulating the immune system responses.
Known as EXO-CD24, this is an exosomes based therapy. According to Dr. Shiran Shapira, director of the lab here, this drug “…is based on exosomes that the body is releasing from the cell mem...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).